Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Income from Continuing Operations (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Income from Continuing Operations for 4 consecutive years, with 66163000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 40.57% to 66163000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 197532000.0 through Dec 2025, up 16.21% year-over-year, with the annual reading at 197532000.0 for FY2025, 16.21% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 66163000.0 at Centessa Pharmaceuticals, down from 54891000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 24886000.0 in Q2 2023, with the low at 111329000.0 in Q4 2024.
  • Average Income from Continuing Operations over 4 years is 50038875.0, with a median of 47079500.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations surged 61.51% in 2023, then plummeted 202.22% in 2024.
  • Over 4 years, Income from Continuing Operations stood at 43173000.0 in 2022, then rose by 14.68% to 36837000.0 in 2023, then tumbled by 202.22% to 111329000.0 in 2024, then skyrocketed by 40.57% to 66163000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 66163000.0, 54891000.0, and 50343000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.